Introduction
The impairment of immunological responsiveness in uraemic patients is well documented. 1'2 All aspects of the immune response appear to be affected by the uraemic state. The numbers, subpopulations and reactivities of circulating lymphocytes may be altered by uraemia. 2'3 This impairment has been implicated in easy susceptibility to infections and increased incidence of malignancy. In addition, various investigators have reported severe structural changes in the lymph nodes 4 and thymus glands of uraemic patients and animals.
The thymus plays an essential role in the development and maintenance of cellular immune competence. 6 Recent evidence suggests that the thymus produces biologically active peptides which are responsible for the differentiation and functional maturation of precursor T-lymphocytes. 7 Thymosin f14, an N-terminal acetylated peptide containing 43 amino acid residues, was first isolated from calf thymus by Low et al. 8 who determined its Abbreviations: Z, benzyloxycarbonyl; OBzl, benzyl ester; Bzl, benzyl; Boc, tert-butoxycarbonyl; Troc, ,,fl-trichloroethoxycarbonyl; Su, N-hydroxysuccinimide; NMM, N-methylmorpholine; OSu, N-hydroxy-succinimide ester; EDTA, ethylenediaminetetraacetic acid; DMF, dimethyl-formamide; DMSO amino acid sequence. This peptide exhibits important activities in the regulation and differentiation of thymus-dependent lymphocytes. 8 It also inhibits the migration of macrophages, and exerts biological effects on the hypothalamus and pituitary.
In our previous papers, 11 we reported syntheses of deacetyl-thymosin f14 and its fragments, and showed that the synthetic deacetyl-thymosin f14 and some of the fragments could have restorative effects on the impaired cell-mediated immunological functions.
We also noticed that the acetyl group at the N-terminal serine residue of thymosin f14, is not required for the restorative effect on the impaired cell-mediated immunological functions. 9 In our preceding paper, 1 we also concluded that the two portions of the amino acid sequence of thymosin /34,-Lys-Leu-Lys-Lys-Thr-Glu-Thr-GlnGlu-Lys-Asn-(positions [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and-Lys-Glu-ThrIle-Glu-Gln-Lys-Gln- ( 
Materials and Methods
General experimental procedures used were essentially the same as described in the previous papers. 13 ' 
Compound (1 g) was treated with TFA-anisole (10 ml-2 ml) as described above. Boc-Met(O)-Su (272 mg) was added to a solution of this product in DMF (10 ml), followed by NMM to keep the solution slightly alkaline. 
. This compound was prepared as follows: Boc-Asp(OBzl) Lys(Z) Ser(Bzl) Lys(Z) Leu- 8.98 (recovery of Gly 84%).
H-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-LysPhe(4F)-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-ThrGln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-IleGlu-Gln-Glu-Lys-Gln-Ala-Gly- Glu 
Results
From a synthetic viewpoint, compared with our previous syntheses of deacetyl-thymosin/349 and its fragments, 1'11 the thioanisole-mediated TFMSA deprotection procedure 13 was applied in the final step of the present synthesis instead of catalytic hydrogenation or hydrogen fluoride.
Our synthetic route to [Phe(4F)12]deacetylthymosin /34 is illustrated in Fig. 1 , which shows three fragments selected as building blocks to 
